Felicity Thomas

Broken String Biosciences and the Francis Crick Institute will collaborate on research into how genome stability impacts ALS.

Progression in biopharmaceutical drug development and manufacturing is being boosted by technological advances.

GSK’s supplemental Biologics License Application for its PD-1-blocking antibody therapy has been accepted for review by FDA.

The new Verafit products from STERIS are designed to help manufacturers conform to regulatory requirements laid out in Annex 1.

The health data science division of Optima Partners, bioXcelerate, has released a tool aimed at accelerating the drug discovery process.

Given the criticality of fill/finish processes, it is clear that automation is the next technological step.

AstraZeneca has completed its acquisition of Icosavax, gaining the IVX-A12 vaccine candidate that targets RSV and hMPV.

GSK is expanding its respiratory biologics portfolio with its acquisition of Aiolos Bio and its novel therapy, AIO-001.

NICE has recommended the use of AbbVie's Tepkinly as a treatment option for eligible adults with diffuse large B-cell lymphoma.

Despite slow growth over recent years, the CAR-T cell therapy space is expected to see considerable advancements in the near future.

IMU Biosciences has secured £11.5 million in its Series A financing round.

The acquisition marks a pivotal expansion for the company into the US market.

CellVoyant has raised £7.6 million in seed funding to speed up the development of novel cell therapies.

The largest biotech hub is set to be built in Lithuania by Northway Group.

Hovione has acquired start-up company, ExtremoChem, expanding its technology platforms.

UK industry body, ABPI, has responded positively to the recent Autumn Statement.

Innovative strategies and good partnerships are means by which developers can overcome the unique challenges in biologics formulation.

The companies will co-promote GSK’s shingles vaccine, Shingrix, to healthcare professionals and points of vaccination in China.

Orakl Oncology has raised funds to develop its precision oncology platform and accelerate drug development.

Biosynth has further strengthened its peptide division with the acquisition of Pepceuticals.

Biologics formulation comes with a unique set of challenges, which can be overcome through innovative strategies and good partnerships.

Samsung Biologics and Bristol Myers Squibb have further expanded their strategic manufacturing agreement to include the large-scale manufacture of an antibody cancer drug substance.

The pandemic and shifting focus to more complex therapeutics are driving growth in the outsourced formulation development services market.

A partnership between Rentschler Biopharma and Ikarovec will support the accelerated development of novel gene therapies for the treatment of eye diseases.

Hanns-Christian Mahler and Andrea Allmendinger from ten23 health will discuss some key aspects of biologic drug development and manufacturing.

Waters Corporation expected to boost growth in bioanalytical characterization for new modalities with acquisition of Wyatt Technology.

Shifting toward more technological solutions and ensuring a greater understanding of the workforce’s needs will give both CROs and sponsors a market advantage.

Guidance for GMP manufacture of emerging therapies has evolved to accommodate innovation and the broader spectrum of products in development, but greater harmonization is still needed.

As the therapeutic landscape grows more complex, so too must the analytical techniques for cleaning validation to ensure the utmost cleanliness is achieved.